Search results
Results from the WOW.Com Content Network
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
The Science of Diabetes Self-Management and Care is a peer-reviewed academic journal that publishes papers in the field of Endocrinology. The journal's editor is James Fain, PhD, RN, BC-ADM, FAAN (University of Massachusetts-Dartmouth). It has been in publication since 1980 and until 2021 was titled The Diabetes Educator. [1]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
The main goal of diabetes management is to keep blood glucose (BG) levels as normal as possible. [1] If diabetes is not well controlled, further challenges to health may occur. [1] People with diabetes can measure blood sugar by various methods, such as with a BG meter or a continuous glucose monitor, which monitors over several days. [2]
The Journal of Diabetes Science and Technology (JDST) is a bimonthly peer-reviewed medical journal covering all aspects of diabetes. JDST covers all aspects of diabetes technology including glucose monitoring; insulin and metabolic peptide delivery; the artificial and bioartificial pancreas, telemedicine; software for modeling; physiologic monitoring; technology for managing obesity ...
Medical journals are published regularly to communicate new research to clinicians, medical scientists, and other healthcare workers. This article lists academic journals that focus on the practice of medicine or any medical specialty. Journals are listed alphabetically by journal name, and also grouped by the subfield of medicine they focus on.
Drugs belonging to this class are: Sitagliptin [6] (FDA approved 2006, marketed by Merck & Co. as Januvia) Vildagliptin [7] (EU approved 2007, marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, marketed as Onglyza) Linagliptin (FDA approved in 2011, marketed as Tradjenta by Eli Lilly and Company and Boehringer ...
The Journal of Pain and Symptom Management is a monthly peer-reviewed medical journal that was established in 1986. It is a continuation of the PRN Forum (Pain Research News forum), a bimonthly journal published from 1982 to 1985. [ 1 ]